CD274 and non-small cell lung carcinoma: Likewise, although pembrolizumab with or without chemotherapy have not been compared directly in the most anti-PD-(L)1 responsive subset of patients with nonsquamous NSCLC (those with TPS ≥ 50%), concurrent 5-year updates of both pivotal trials (KEYNOTE-042 and KEYNOTE-189) showed similar OS HRs of the pembrolizumab containing versus chemotherapy only arms [pembrolizumab only: 0.68 (0.57--0.81); pembrolizumab + chemotherapy: 0.68 (0.49–0.96; refs. 39, 40)], arguing strongly against substantial synergy between chemotherapy and pembrolizumab in this indication (23).